267 related articles for article (PubMed ID: 29363022)
21. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
22. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
El Khoury A; Patel C; Huang A; Wang L; Bashyal R
Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
[No Abstract] [Full Text] [Related]
23. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
[TBL] [Abstract][Full Text] [Related]
24. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
[TBL] [Abstract][Full Text] [Related]
25. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
[TBL] [Abstract][Full Text] [Related]
26. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study.
Mahabaleshwarkar R; Lin D; Fishman J; Blair T; Hetherington T; Palmer P; Patel C; Benson C; Joshi K; Krull C; Tcheremissine OV
Adv Ther; 2021 Apr; 38(4):1958-1974. PubMed ID: 33704681
[TBL] [Abstract][Full Text] [Related]
28. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
29. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
[TBL] [Abstract][Full Text] [Related]
30. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.
Young-Xu Y; Duh MS; Muser E; DerSarkissian M; Faust E; Kageleiry A; Bhak RH; Fu DJ; Lefebvre P; Shiner B
J Clin Psychiatry; 2016 Oct; 77(10):e1332-e1341. PubMed ID: 27574835
[TBL] [Abstract][Full Text] [Related]
31. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
[No Abstract] [Full Text] [Related]
32. Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.
El Khoury AC; Patel C; Mavros P; Huang A; Wang L; Bashyal R
Neuropsychiatr Dis Treat; 2021; 17():3159-3170. PubMed ID: 34703236
[TBL] [Abstract][Full Text] [Related]
33. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
[TBL] [Abstract][Full Text] [Related]
34. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
35. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.
Pilon D; Amos TB; Kamstra R; Manceur AM; El Khoury AC; Lefebvre P
Curr Med Res Opin; 2019 Jan; 35(1):41-49. PubMed ID: 30106313
[No Abstract] [Full Text] [Related]
36. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
[TBL] [Abstract][Full Text] [Related]
37. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
38. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
[TBL] [Abstract][Full Text] [Related]
39. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
40. A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China.
Liu J; Wang Q; Su L; Yang L; Zou L; Bai L
BMC Psychiatry; 2022 Feb; 22(1):95. PubMed ID: 35135512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
